Autopsy report · NCT00998738

Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer

“lack of accrual”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 2 months before it stopped.
• 1 participant enrolled.
• Results were posted on the registry 7 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Mayo Clinic

Sponsor type

University, hospital or other

Conditions

Neuropathy; Pain; Recurrent Breast Carcinoma; Stage IV Breast Cancer

Interventions

Calcium Gluconate; Magnesium Sulfate; Placebo; Quality-of-Life Assessment; Questionnaire Administration; Ixabepilone

Participants

1

Sites

1

Countries

United States

Trials that died the same way

• Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma
  “Lack of adequate accrual.” (92% match in meaning)
• Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth
  “Inadequate accrual” (90% match in meaning)
• Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
  “Severe lack of accrual” (90% match in meaning)
• FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
  “Poor Accrual” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.